co.don AG works in the relatively young field of tissue engineering/regenerative medicine at the interface between the pharmaceutical industry and biotechnology.
Since 1993 we have been developing, producing and marketing autologous, cell-based pharmaceutical products for the biological repair, regeneration and functional maintenance of the musculoskeletal system.
Our competence is the culturing of autologous tissue for the biological regeneration of articular and vertebral cartilage defects.
co.don AG has been listed on the stock exchange since February 2001.
In 1997 co.don AG became the first biopharmaceutical company to obtain a production license for autologous chondrocyte transplants under Section 13 of the German Pharmaceutical Products Act (AMG).